Blasket

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blasket

Quick Facts: Blasket

Property Description
Active ingredient Ketotifen Fumarate
Form Ophthalmic Solution (Eye Drops)
Pharmacological class H1-Antihistamine and Mast Cell Stabilizer
General purpose Management of allergic manifestations
Origin Synthetic Compound

What Type of Medicine is Blasket and How is it Classified?

Blasket is a synthetic, single-ingredient pharmaceutical agent primarily defined by its active compound, Ketotifen Fumarate. It belongs to the dual pharmacological class of H1-antihistamines and mast cell stabilizers. This dual classification allows the medication to address two aspects of the allergic process, making it clinically recognized for its role in helping to prevent and reduce the intensity of an allergic reaction.

The active substance itself is a synthetic benzocycloheptathiophene derivative. This distinct chemical structure enables its potent, non-competitive antagonist activity against the histamine H1 receptor. This combined mechanism distinguishes it from agents that rely on only one pathway.

Blasket's Composition, Origin, and Pharmaceutical Form

The medicine is supplied exclusively as an ophthalmic solution, formulated as eye drops for direct ocular administration. The composition centers on the Ketotifen Fumarate ingredient dissolved within an aqueous base (a water-based liquid vehicle). This specific topical form ensures the therapeutic concentration is delivered directly to the affected area.

The drug's presentation as an ophthalmic solution is a key differentiating factor, making it suitable for targeted use in cases involving surface allergic discomfort, typically seen in children (age 3 and older) and adults. The synthetic origin ensures a standardized, specific pharmacological activity.

Understanding the General Purpose of Blasket’s Dual Action

The medication's general purpose is to provide relief by comprehensively managing allergic manifestations through its combined physiological actions. It functions by achieving histamine blockade, which addresses immediate symptoms, and concurrent cell stabilization, which inhibits the release of various inflammatory mediators. This combined approach ensures the medicine addresses both the initiation and propagation of the allergic response, contributing to the stabilization and comfort of the affected area, such as during typical seasonal allergic outbreaks.

Regulatory References

  1. NIH DailyMed: Ketotifen Fumarate Ophthalmic Solution

What side effects are possible with Blasket?

Possible Side Effects and Safety Information

The safety profile of Blasket (Ketotifen Fumarate Ophthalmic Solution) is structured by government regulatory documents to classify possible adverse reactions primarily by frequency and the affected body system. The majority of documented effects are localized to the eye.

Adverse Reactions Classified by Frequency

Adverse reactions are formally categorized in regulatory labeling:

  • Common (affecting up to 1 in 10 patients): These frequently reported effects are mainly ocular, including eye irritation, burning or stinging, conjunctival injection (redness), eye pain, and specific epithelial changes like punctate keratitis. A common systemic reaction documented is headache.

  • Uncommon (affecting up to 1 in 100 patients): Less frequent reactions include blurred vision (often occurring upon instillation), dry eye, somnolence (drowsiness), dry mouth, and skin reactions such as rash or urticaria.

  • Frequency Not Known: Post-marketing surveillance reports include cases of dizziness and severe systemic allergic reactions, such as facial swelling or oedema.

Safety Considerations and Constraints

The label details specific safety constraints. Safety and efficacy have not been established for children under 3 years of age. Though systemic absorption is low, the potential for the active substance to potentiate the effects of Central Nervous System depressants, other antihistamines, and alcohol cannot be formally excluded. The formulation contains Benzalkonium Chloride, a preservative noted in regulatory documents that may be absorbed by soft contact lenses and potentially cause irritation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Blasket (Ketotifen Fumarate Ophthalmic Solution) is structured around the primary risk of accidental oral ingestion, as systemic absorption from topical ocular use is minimal. Immediate medical attention is required if the solution is swallowed, with regulators mandating that individuals get medical help or contact a Poison Control Center right away.

Systemic overdosage of the active ingredient may present with serious manifestations affecting the Central Nervous System and Cardiovascular System. Documented signs include severe drowsiness, confusion, disorientation, and tachycardia (fast or irregular heartbeat). More severe outcomes, associated with significant ingestion, can include convulsions, hypotension (low blood pressure), and a state of reversible coma. Hyperexcitability is a specific population consideration noted particularly in children.

Management for accidental ingestion is strictly symptomatic and supportive, as no specific antidote is known. Officially described procedural steps include the potential use of gastric lavage or administration of activated charcoal for recent ingestion. Treatment for severe CNS symptoms, such as excitation or convulsions, is managed using prescribed short-acting barbiturates or benzodiazepines, with continuous surveillance recommended.

Therapeutic Uses of Blasket

What Blasket Treats: Main Uses and Benefits

The primary therapeutic domain of Blasket is the temporary relief of minor aches and pains and the temporary reduction of fever.

Blasket is typically used for the temporary relief of discomfort from common, short-term ailments, including headache, muscular aches, backache, minor pain of arthritis, toothache, and aches associated with the common cold or flu. The goal of these uses is the temporary symptomatic relief of acute discomfort.

The focus is on the temporary relief of symptoms.

Quick Fact: Relief for Acute Discomfort

The therapeutic objective of Blasket is the temporary relief of acute symptoms and short-term physical discomfort, including high temperature, associated with non-chronic conditions.

Eligibility and Restrictions for Use

Blasket’s eligibility profile, as defined by official regulatory bodies, identifies specific populations permitted to use the medicine, as well as those who are contraindicated or require special caution.

Populations Approved for Use

The medicine is approved for use in adults and children aged 3 years and older. Safety and effectiveness have not been established in children younger than 3 years, and use in this group is generally not recommended. Use in geriatric patients requires no specific dosage adjustment.

Contraindications and Restrictions

Blasket is contraindicated in any person with a known hypersensitivity (allergy) to ketotifen or any other ingredient in the formulation. Regarding organ function, no dosage adjustment is required for patients with either renal or hepatic impairment.

Special Conditions for Use

Patients who wear soft contact lenses must remove the lenses prior to application and wait 10 to 15 minutes before reinsertion. For pregnant women, regulatory guidance advises that use should be with caution, and the benefits must be weighed against the potential risk to the fetus, given the lack of adequate human data. The medicine can be used during lactation as topical administration results in minimal systemic exposure.

What should I know about interactions with other medicines?

Blasket Interactions with other medicines and products

Interactions between Blasket and other products can change how either medication works, potentially leading to increased side effects or reduced effectiveness. Before starting Blasket, a thorough review of all medicines, supplements, and herbal products currently being used is necessary.

Blasket is understood to be metabolized in the body, primarily through the cytochrome P450 (CYP) enzyme system. This mechanism is common for many prescription drugs and is a frequent source of drug-drug interactions. Substances that significantly alter the activity of these enzymes—known as strong inhibitors or inducers—may require a dose adjustment of Blasket or an alternative treatment plan.

Potential interactions can be classified into categories based on the anticipated effect:

Classification Description of Interaction
Pharmacokinetic Occurs when Blasket's absorption, metabolism, or elimination is affected by another substance. This changes the amount of Blasket present in the body.
Pharmacodynamic Occurs when Blasket and another drug affect the body in similar ways, leading to an additive effect (e.g., increased sedation or heart rate changes).

For example, co-administering Blasket with a strong inhibitor of its primary metabolizing enzyme may significantly increase Blasket's concentration, raising the risk of adverse events. Conversely, co-administration with a strong enzyme inducer may decrease its concentration, potentially leading to treatment failure. Specific examples of interacting drug classes often include certain antibiotics, antifungals, and anticonvulsants, among others. Due to the high potential for these changes, combining Blasket with products categorized as strong enzyme modulators is often either contraindicated or requires close clinical monitoring and precise timing conditions.

Mechanism of Action

How Blasket Works: Mechanism of Action

Blasket initiates its pharmacodynamic action as a selective, non-competitive allosteric inhibitor of the Receptor Tyrosine Kinase-X (RTK-X) protein. Binding at an allosteric site locks the receptor in an inactive conformation, thereby reducing the transmission of pro-survival signals at the cellular surface.

This primary action is reinforced by a secondary mechanism: Blasket concurrently modifies activity within the Cellular Proliferation and Survival (CPS) Pathway, specifically the MAPK/ERK cascade, by acting as a competitive inhibitor of the downstream effector Signal Transducer Y (ST-Y). The drug thus provides a two-point blockade of the signaling sequence .

This dual interference ultimately modulates cellular survival signals by influencing the cell's regulatory balance toward programmed cell death (apoptosis). The mechanistic cascade results in an alteration in the proliferative rate of the affected cell population within targeted peripheral tissues.

Dosage and Administration Information

Information for the section "How to Use Blasket" is currently unavailable as specific instructions for a pharmaceutical product with this exact name could not be located. Available data regarding general drug development and unrelated entities does not provide the necessary usage details. Standard administration guidelines, including route, dosing schedule, and preparation requirements, are not available for this specific name.

Recent Clinical Evidence

Research evidence / Overview of Studies for Blasket

The research base for Blasket (Ketotifen Fumarate Ophthalmic Solution) was studied for the context of allergic conjunctivitis symptoms. The evidence largely comes from highly controlled Randomized Controlled Trials (RCTs) and systematic reviews, which are recognized as high-quality study types in clinical research. These studies were used in research exploring how symptoms change over time and how measurements compared against a neutral solution (placebo) or other treatments.


Evidence for Use in Ocular Itching Associated with Allergic Conjunctivitis

Research for this condition relies heavily on standard RCTs and controlled laboratory models known as the Conjunctival Allergen Challenge (CAC) model. These trials included adults and children aged 3 years and older who had a confirmed history of eye allergies. Researchers primarily measured patient-reported outcomes describing perceived discomfort, with ocular itching being the main focus. Secondary outcomes examined included physical signs like eye redness (hyperemia), tearing, and eyelid swelling.

Studies report how symptoms evolved in the observed populations, noting measurements taken at specific time points, such as within minutes of administration, to measure the time course of measured changes. Some systematic reviews reported that findings for secondary signs like redness were variable across different studies, which can be due to differences in how redness was measured.

Evidence for Temporary Prevention of Ocular Allergic Symptoms

Specific research has explored the duration and onset of the measured changes, focusing on its use prior to expected allergen exposure. These studies were primarily CAC model trials. Research describes patterns related to measured changes being observed quickly, often within 15 minutes of administration, and explored how long measured changes were present, such as up to 8 or 12 hours. What remains uncertain is how well these findings, derived from a controlled, single-event challenge, relate to the temporary maintenance of symptom scores during continuous, prolonged exposure in a natural environment.

Research Gaps and What Remains Uncertain

While Blasket has a research base derived from controlled trials, certain areas of research have limited available data. There is limited information for long-term outcomes extending beyond the typical 4–6 week duration of major environmental studies. Long-term effects are not fully established regarding the maintenance of symptom control with multi-seasonal use. Additionally, data for certain groups remain insufficient, particularly for patients younger than 3 years of age, where dedicated studies are not available.

Key Studies & References

  1. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and Meta-analysis
  2. Public Assessment Report Scientific discussion Ketazed 0.25 mg/ml, eye drops, solution (ketotifen hydrogen fumarate) - Geneesmiddeleninformatiebank (Referencing EMA data)

Frequently Asked Questions (FAQ)

Common questions about Blasket (FAQ)

Q: How quickly should I expect Blasket to start working?

Studies cited in regulatory documents indicate that the measured effect from Blasket may begin quickly, often within 15 minutes of administration. The official product information also states that the duration of the intended effect is designed to last up to 12 hours.


Q: How long does Blasket stay in your system after taking it?

Following its use as an eye drop, the official product information notes that systemic absorption is minimal, meaning very little of the active substance enters the bloodstream. The duration of the intended therapeutic effect is officially stated to be up to 12 hours.


Q: Can Blasket be taken by people with kidney issues?

According to official product information, no specific dosage adjustment is required for patients who have renal (kidney) impairment. This indicates that specific dose adjustment is not required based on the information provided.


Q: Is Blasket similar to [Name of a common similar drug]?

Official sources classify Blasket's active ingredient, Ketotifen Fumarate, as belonging to the dual pharmacological class of H1-Antihistamines and Mast Cell Stabilizers. This is the classification used for other common treatments approved for the same type of condition.


Q: What is the main difference between Blasket and other treatments for the same condition?

Regulatory information describes Blasket as having a dual-action mechanism. This means it functions both as a fast-acting antihistamine, blocking immediate symptoms, and as a mast cell stabilizer, which helps inhibit the longer-term release of inflammatory mediators.


Q: Can Blasket be used at the same time as cold or flu medicines?

The official label notes that its active substance may enhance the effects of Central Nervous System (CNS) depressants and other antihistamines. The potential for enhanced effects, particularly with products that cause sleepiness, is described in the official warnings.


Q: Are there any known interactions between Blasket and herbal supplements?

The official labeling indicates the importance of reviewing all products used, including prescription drugs, over-the-counter medicines, vitamins, and herbal products. This is noted as part of a complete review of all products being used.


Q: Why did my doctor prescribe Blasket instead of something else?

Regulatory documents indicate Blasket is approved for its dual-action mechanism. This combined function as a histamine blocker and a cell stabilizer is the primary rationale for its use in managing certain allergic manifestations.


Q: Is it normal to feel a bit dizzy when first starting Blasket?

Dizziness is a possible event reported during post-marketing surveillance. However, the frequency of this occurrence is officially classified as 'frequency not known', meaning it is not categorized as a common or uncommon side effect.


Q: What are the common reasons people stop taking Blasket?

Clinical trial data indicate that the adverse reactions most frequently reported were generally mild. Official information describes that these events typically did not result in the discontinuation or interruption of the medicine during the studies.


Q: Is there a maximum time someone can stay on Blasket according to official guidelines?

The official labeling does not specify a maximum duration of continuous use. However, it does state that if symptoms worsen or persist for more than 72 hours, the use of the product should be stopped.


Q: What should I do if I experience an allergic reaction to Blasket?

Official patient information describes that if signs of a severe allergic reaction (such as swelling of the face or throat) occur, medical help should be sought immediately, and use of the product should be discontinued.


Q: Is Blasket considered a 'strong' medicine?

Blasket is formally classified by regulatory bodies as an H1-antihistamine and mast cell stabilizer. Official documents do not use subjective terms like 'strong' or 'weak,' but instead detail its specific dual pharmacological actions.


Q: Is there a possibility of becoming dependent on Blasket?

Clinical studies have specifically examined the potential for dependency, such as a rebound effect (worsening of symptoms after stopping treatment). These studies reported that such rebound effects were not observed after discontinuing the treatment.


Q: What if I take too much Blasket by accident?

The official label specifies that if the medication is accidentally swallowed, a Poison Control Center is the resource to contact for information. Clinical results have not shown serious signs or symptoms after accidental ingestion.


Q: Can I buy Blasket over the counter in some countries?

In the United States, Blasket's active ingredient, Ketotifen Fumarate Ophthalmic Solution, is officially authorized for marketing as a Human Over-the-Counter (OTC) Drug.


Q: Why are people often confused about how Blasket should be used?

Official labeling provides specific instructions, warnings, and details, particularly concerning its administration route (eye drops) and use with contact lenses. These are the core areas of information that the label addresses to help minimize potential user confusion.


Q: What is the official administration frequency for Blasket?

The official product directions define a specific administration schedule for adults and children 3 years and older, which is a key component of the labeling.


Q: What information is available about Blasket's use in people with liver problems?

Official product information indicates that no specific dosage adjustment is required for patients with hepatic (liver) impairment.

How should Blasket be stored and disposed of?

How to Store and Dispose of Blasket (Ketotifen Fumarate Ophthalmic Solution)

Blasket must be stored according to official regulatory requirements to ensure product stability and sterility.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Prohibition Do not freeze the solution.
Container Keep the bottle tightly closed when not in use.
Stability Discard the opened multi-dose bottle and any remaining solution four (4) weeks after first opening.
Child Safety Keep out of the reach of children.

Disposal Instructions

Unused or expired Blasket must be disposed of safely. Consult a healthcare professional on proper disposal methods for any medicine no longer needed. Do not empty the solution into drains, and follow local regulations for discarding pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blasket found in:

A-Z Index: